TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21031342

Group type: EXPERIMENTAL
Intervention: Protease-inhibitor-modulating-matrix (ORC/collagen matrix) changed daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Good standard wound care
Number of subjects: 19
Study: 19387178

Group type: EXPERIMENTAL
Intervention: Epidural etanercept 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural etanercept 4 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural etanercept 6 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural saline (Control)
Number of subjects: 24
Study: 17979587

Group type: EXPERIMENTAL
Intervention: Once-daily multilayer-release methylphenidate (MLR) at a stable dose of 32.0 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Twice-daily immediate-release methylphenidate (IR-MPH) at a stable dose of 32.5 mg
Number of subjects: 90
Study: 15530203

Group type: EXPERIMENTAL
Intervention: Bullying alone among girls
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Bullying alone among boys
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Bullying in groups among girls
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Bullying in groups among boys
Number of subjects: 117
Study: 11495122

Group type: EXPERIMENTAL
Intervention: Subjects with low working-memory capacities who detected their name in an irrelevant message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects with higher working-memory capacities (implied control group)
Number of subjects: 0
Study: 9671000

Group type: EXPERIMENTAL
Intervention: abciximab with low-dose weight-adjusted heparin
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo with standard-dose, weight-adjusted heparin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: abciximab (combined analysis from EPIC and EPILOG trials)
Number of subjects: 144

Group type: COMPARATOR
Intervention: DCA patients compared to PTCA patients
Number of subjects: 144
Study: 7821192

Group type: EXPERIMENTAL
Intervention: Retrograde cannulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antegrade cannulation
Number of subjects: 0
Study: 2688764

Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 0
Study: 1103576

Group type: EXPERIMENTAL
Intervention: Clonidine (rapidly falling dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study: 31270800

Group type: EXPERIMENTAL
Intervention: Inhaled aerosolised prostacyclin (20 ng/kg/min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inhaled saline (NaCl, 9 mg/mL)
Number of subjects: 22
Study: 28911799

Group type: EXPERIMENTAL
Intervention: Topical clobetasol proprionate (CP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical betamethasone diproprionate (BDP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 16
Study: 26609891

Group type: EXPERIMENTAL
Intervention: Perospirone or aripiprazole
Number of subjects: 100
Study: 23955418

Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pregabalin (200 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20862509

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19245725

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 68
Study: 17131249

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium hyaluronate eye drops twice daily
Number of subjects: 10
Study: 15590250

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (0.05 mg) with mepivacaine (100 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (0.1 mg) with mepivacaine (100 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (0.15 mg) with mepivacaine (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (0 mg neostigmine) with mepivacaine (100 mg)
Number of subjects: 40
Study: 11392367

Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based video education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no formal asthma education)
Number of subjects: 0
Study: 9463302

Group type: EXPERIMENTAL
Intervention: Pectin/chamomile extract preparation (Diarrhoesan)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 8076074

Group type: EXPERIMENTAL
Intervention: Right atrial appendicectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saving the right atrial appendix
Number of subjects: 20
Study: 3525428

Group type: COMPARATOR
Intervention: Gabapentin 200-400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gabapentin 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gabapentin 50-200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gabapentin (various doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28636433

Group type: EXPERIMENTAL
Intervention: AGS‐004 dendritic cell therapy administered monthly after ART initiation during acute HIV infection
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AGS‐004 dendritic cell therapy
Number of subjects: 6
Study: 27633780

Group type: EXPERIMENTAL
Intervention: Self-report method
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Chart-stimulated recall method
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Behavioral rehearsal method
Number of subjects: 135

Group type: COMPARATOR
Intervention: Direct observation (gold-standard)
Number of subjects: 135
Study: 25185281

Group type: EXPERIMENTAL
Intervention: SIT (standardized allergen vaccine) for 3 years
Number of subjects: 102

Group type: COMPARATOR
Intervention: ST (symptomatic therapy)
Number of subjects: 102
Study: 23782816

Group type: EXPERIMENTAL
Intervention: Community resource centers (intervention)
Number of subjects: 24000
Study: 20728275

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose of naloxone (0.02 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose of naloxone (0.14 mg/kg)
Number of subjects: 0
Study: 18266852

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/40 mg
Number of subjects: 424

Group type: COMPARATOR
Intervention: Doubling the statin dose
Number of subjects: 424
Study: 16009156

Group type: EXPERIMENTAL
Intervention: Oral administration of levonorgestrel (1.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaginal administration of levonorgestrel (1.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 30
Study: 12834639

Group type: EXPERIMENTAL
Intervention: Warm contrast medium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold contrast medium
Number of subjects: 100
Study: 10638905

Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia (PCIA) with ropivacaine 0.2%
Number of subjects: 35

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIVA) with nicomorphine
Number of subjects: 35
Study: 8964871

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular insulin (RI)
Number of subjects: 12
Study: 1515660

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg b.i.d.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 6366809

Group type: EXPERIMENTAL
Intervention: 750 mg naproxen daily for 7 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: 2 g acetylsalicylic acid daily for 7 days
Number of subjects: 79
Study: 30216238

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Shorter sedentary bouts (1-4 min)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Longer sedentary bouts (5-9 min, 10-14 min, ≥15 min)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST) and breaks in sedentary time (BST/ST)
Number of subjects: 333
Study: 28840431

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no photobiomodulation therapy)
Number of subjects: 27
Study: 26969188

Group type: EXPERIMENTAL
Intervention: Structured education for GPs
Number of subjects: 785
Study: 24405028

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-stretching (control condition)
Number of subjects: 38
Study: 21676554

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) plus vaginal brachytherapy (VBT)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Vaginal irradiation alone (VBT)
Number of subjects: 527
Study: 20197772

Group type: EXPERIMENTAL
Intervention: Adenovirus DNA detection in Guthrie cards
Number of subjects: 243

Group type: COMPARATOR
Intervention: Matched controls (no adenovirus DNA detected)
Number of subjects: 243
Study: 17503668

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART) with zidovudine/lamivudine
Number of subjects: 139
Study: 16803794

Group type: EXPERIMENTAL
Intervention: Widex Diva SP3 device with stimulus generated by Widex Diva SD-9 hearing aid
Number of subjects: 43
Study: 12642825

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 322
Study: 11116663

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 37000
Study: 8814744

Group type: EXPERIMENTAL
Intervention: Topical ganciclovir 0.15% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical acyclovir 3% ointment
Number of subjects: 0
Study: 1711089

Group type: EXPERIMENTAL
Intervention: Combination therapy (radiation and hyperthermia with bleomycin)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Radiation alone (50-70 Gy)
Number of subjects: 56
Study: 6601941

Group type: EXPERIMENTAL
Intervention: Propranolol therapy continued intraoperatively and postoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propranolol therapy discontinued
Number of subjects: 100
Study: 31583748

Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training (CBCT) administered for 20 hours across 8 to 10 weeks to parents (n = 25)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waitlist control group (n = 14)
Number of subjects: 39
Study: 31090751

Group type: EXPERIMENTAL
Intervention: Minimally invasive flap
Number of subjects: 17

Group type: COMPARATOR
Intervention: Trapezoidal flap
Number of subjects: 17
Study: 28576403

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PHACO)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Small incision cataract surgery (SICS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both PHACO and SICS
Number of subjects: 57
Study: 26135275

Group type: EXPERIMENTAL
Intervention: Peer support intervention; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on intervention not available.
Number of subjects: 0
Study: 23638803

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (Ozurdex)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sectorial laser photocoagulation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Panretinal laser photocoagulation
Number of subjects: 102
Study: 21185347

Group type: EXPERIMENTAL
Intervention: OROS®-methylphenidate hydrochloride (MPH) 18, 36 or 72 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19723572

Group type: EXPERIMENTAL
Intervention: Fraxinus excelsior L. seed extract (1.0 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (wheat bran)
Number of subjects: 16
Study: 17257972

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 212

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study: 15189519

Group type: EXPERIMENTAL
Intervention: Pacing from nontraditional or alternate sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional right-sided pacing sites (right ventricular apex and right atrial appendage)
Number of subjects: 0
Study: 11378344

Group type: EXPERIMENTAL
Intervention: Mitoxantrone + Vinorelbine (MV)
Number of subjects: 281

Group type: COMPARATOR
Intervention: 5‐fluorouracil + cyclophosphamide + doxorubicin/epirubicin (FAC/FEC)
Number of subjects: 281
Study: 10332317

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 21
Study: 8352508

Group type: EXPERIMENTAL
Intervention: Immediate laparoscopy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Laboratory contrast or imaging approach
Number of subjects: 65
Study: 3544892

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg orally over three days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg orally over three days)
Number of subjects: 14
Study: 29704487

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 357

Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 357
Study: 26408398

Group type: EXPERIMENTAL
Intervention: Fat talk
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Positive body talk
Number of subjects: 85

Group type: COMPARATOR
Intervention: Neutral talk
Number of subjects: 85
Study: 24759586

Group type: EXPERIMENTAL
Intervention: Disposable circumcision suture device (DCSD)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Conventional circumcision
Number of subjects: 942
Study: 22640511

Group type: EXPERIMENTAL
Intervention: Extension of the intensive phase by 1 month
Number of subjects: 1871

Group type: COMPARATOR
Intervention: No extension of the intensive phase
Number of subjects: 1871
Study: 20800193

Group type: EXPERIMENTAL
Intervention: Defocused extracorporeal shock wave therapy (ESWT, 100 impulses/cm(2) at 0.1 mJ/mm(2)) applied once to the donor site, immediately after skin harvest
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard topical therapy (nonadherent silicone mesh and antiseptic gel) without ESWT
Number of subjects: 28
Study: 18304131

Group type: EXPERIMENTAL
Intervention: 3M Steri‐Strip S Surgical Skin Closure System
Number of subjects: 26

Group type: COMPARATOR
Intervention: Subcuticular suture closure with a skin sealant
Number of subjects: 26
Study: 16567984

Group type: EXPERIMENTAL
Intervention: Zidovudine exposure in utero for >7.5 weeks
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Zidovudine exposure
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Total and postnatal duration of zidovudine exposure
Number of subjects: 1408
Study: 12706439

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily for 6 weeks
Number of subjects: 63
Study: 10736124

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) administered for 100 minutes (150 mg/kg over 1 hour followed by 14 mg/kg per hour for 40 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 0
Study: 9369111

Group type: EXPERIMENTAL
Intervention: 2 liters of polyethylene glycol solution combined with a laxative (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4 liters of polyethylene glycol solution (Group B)
Number of subjects: 100
Study: 1396535

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) monotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Phenytoin (PHT) monotherapy
Number of subjects: 29
Study: 3994616

Group type: EXPERIMENTAL
Intervention: dimenhydrinate (50 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: promethazine hydrochloride (25 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: mixture (25 mg promethazine plus 10 mg d-amphetamine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: dimenhydrinate (100 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: promethazine (50 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: lactose placebo
Number of subjects: 70
Study: 30023451

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Cognitive Behavioural Therapy (MI-CBT) in addition to Treatment as Usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study: 28701387

Group type: EXPERIMENTAL
Intervention: Moderate iron status (serum ferritin 12-75 μg/L)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: High iron status (serum ferritin ≥75 μg/L)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: High iron status with inflammation-corrected serum ferritin
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: High iron status with normal serum soluble transferrin receptor concentration (<8.3 mg/L)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Deficient iron status (serum ferritin <12 or <15 μg/L)
Number of subjects: 745
Study: 25512653

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation with lower tidal volumes
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Conventional ventilation with higher tidal volumes
Number of subjects: 1348
Study: 24093978

Group type: EXPERIMENTAL
Intervention: Ormeloxifene 30 mg, twice a week for 3 months
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 21962052

Group type: EXPERIMENTAL
Intervention: 1 L O2 · min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 L O2 · min(‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no oxygen supplementation during the first walk test)
Number of subjects: 0
Study: 18267048

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-neomycin cream and nasal cautery
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-neomycin cream alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (cautery only)
Number of subjects: 88
Study: 16894588

Group type: EXPERIMENTAL
Intervention: Treatment-resistant late-onset depressive disorder
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treatment-responsive late-onset depressive disorder
Number of subjects: 29
Study: 12853504

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg bid
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 10372230

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9046503

Group type: EXPERIMENTAL
Intervention: External cooling system with physiological saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: External cooling system with bupivacaine/morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group (physiological saline)
Number of subjects: 50
Study: 2001806

Group type: EXPERIMENTAL
Intervention: Portacaval anastomosis
Number of subjects: 82

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 82
Study: 6305479

Group type: EXPERIMENTAL
Intervention: Glioblastoma multiforme (GBM)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Astrocytoma with atypical or anaplastic features (AAF)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Astrocytoma Grade 3
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Astrocytoma Grade 4
Number of subjects: 503
Study: 30870563

Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program
Number of subjects: 278
Study: 29107928

Group type: EXPERIMENTAL
Intervention: Physical practice with free eye movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational practice with free eye movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical practice with instructed fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational practice with instructed fixation
Number of subjects: 0
Study: 26857821

Group type: EXPERIMENTAL
Intervention: Visual inspection associated to radiographic examination
Number of subjects: 250

Group type: COMPARATOR
Intervention: Visual inspection performed alone
Number of subjects: 250
Study: 24826958

Group type: EXPERIMENTAL
Intervention: Three positive things in life intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Value in Action (VIA) signature strengths intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 22795291

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet pattern adhering to American Heart Association recommendations
Number of subjects: 0
Study: 21123342

Group type: EXPERIMENTAL
Intervention: Integrated intervention (systematic health education, intensive and individualised intervention, treatment, and rehabilitation)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Integrated intervention
Number of subjects: 872

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 872
Study: 17220745

Group type: EXPERIMENTAL
Intervention: HUD‐VASH (with Section 8 vouchers and intensive case management)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Case management only
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard VA care
Number of subjects: 460
Study: 15669709

Group type: EXPERIMENTAL
Intervention: One-stage procedure with a two-piece implant and a 3-month healing period (Group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Two-stage procedure with a two-piece implant and a 3-month healing period (Group B - Control Group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: One-stage procedure with a one-piece implant and a 3-month healing period (Group C)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: One-stage surgical procedure with a two-piece implant and early loading (within 3 weeks) (Group D)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Two-stage surgery (Group B - Control Group)
Number of subjects: 108
Study: 11843516

Group type: EXPERIMENTAL
Intervention: CABG + mitral annuloplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 0